Pfizer (PFE)

Geographic Segments

Business Unit / Product Segments

Major Customers (% of Revenue)

Operational KPIs

Deferred revenues (backlog)

Manufacturing plants (capacity)

Cash and cash equivalents (cash_and_equivalents)

Asbestos claims (claims_count)

Common Stockholders (customers)

Countries and territories supplied (customers_served)

GEP amortization of intangible assets (depreciation_amortization)

Cash dividends declared per share (dividends_per_share)

Effective tax rate (effective_tax_rate)

Recognitions given (engagement)

Goodwill (goodwill)

Employees (headcount)

Identifiable intangible assets (intangible_assets)

GEP noncurrent inventories (inventory_units)

Long-term debt (long_term_debt)

BNT162b2 doses contracted (order_book)

Additional U.S. Government doses ordered (orders_received)

Accounts payable (other)

Accounts receivable (other)

Accruals for revenue deductions (other)

Accruals for revenue deductions - Other current liabilities (other)

Accruals for revenue deductions - Other noncurrent liabilities (other)

Accruals for revenue deductions - Trade accounts receivable (other)

Accrued compensation (other)

Accrued compensation and related items (other)

Accrued rebates (other)

Accumulated amortization of finite-lived intangible assets (other)

Accumulated amortization of identifiable intangible assets (other)

Accumulated amortization of intangibles (other)

Accumulated other comprehensive loss (other)

Accumulated other comprehensive loss - Actuarial Gains/(Losses) (other)

Accumulated other comprehensive loss - Available-For-Sale Securities (other)

Accumulated other comprehensive loss - Derivative Financial Instruments (other)

Accumulated other comprehensive loss - Foreign Currency Translation Adjustments (other)

Accumulated other comprehensive loss - Prior Service (Costs)/Credits and Other (other)

Acquisition-related costs (other)

Actuarial gains/losses (other)

Additional paid-in capital (other)

Additional workforce reduction accruals (other)

Adjusted Cost of Sales Guidance (other)

Adjusted Diluted EPS Guidance (other)

Adjusted Other (Income)/Deductions Guidance (other)

Adjusted R&D Guidance (other)

Adjusted Revenues Guidance (other)

Adjusted SI&A Guidance (other)

Adjusted cost of sales guidance (other)

Adjusted diluted EPS (other)

Adjusted diluted EPS guidance (other)

Adjusted other (income)/deductions guidance (other)

Adjusted research and development expenses guidance (other)

Adjusted selling, informational and administrative expenses guidance (other)

Advertising expense (other)

Advertising expenses (other)

Aggregate Market Value of Voting Stock (other)

Aggregate fair value of derivative instruments in a net liability position (other)

Aggregate gross accounts receivable from challenging European markets (other)

Aggregate notional amount of FX derivatives (other)

Aggregate notional amount of foreign exchange derivative financial instruments (other)

Aggregate notional amount of foreign exchange derivatives (other)

Aggregate notional amount of interest rate derivative financial instruments (other)

Aggregate notional amount of interest rate derivatives (other)

Alliance agreements (other)

Alliance revenue (other)

Alliance revenues (other)

Alliances (other)

Allowance for doubtful accounts (other)

Amortization expense (other)

Amortization of intangible assets (other)

Amounts due from bank counterparties (other)

Amounts payable to BioNTech (other)

Animal Health revenue (other)

Animal health R&D programs (other)

Annual cost savings from 2014-2016 program (other)

Annual cost savings from Hospira acquisition (other)

Annual cost synergies targeted (other)

Annualized cost savings (other)

Annualized efficiency benefit (other)

Annualized restructuring benefit (other)

Anticipated annual cost synergies (other)

Anticipated cost savings (other)

Anticipated negative impact of foreign exchange on adjusted diluted EPS (other)

Anticipated negative impact of foreign exchange on revenues (other)

Anticipated negative revenue impact from generic and biosimilar competition (other)

Anticipated net cost savings (other)

Application software count (other)

Aricept countries launched (other)

Aricept market share (other)

Aricept sales (other)

Asbestos Claims Pending (other)

Asbestos claims pending (other)

Asbestos personal injury claims pending (other)

Assumed diluted weighted-average shares outstanding for 2017 guidance (other)

AtS cost savings (other)

AtS restructuring accrual (other)

AtS total costs (other)

Available-for-sale debt securities (other)

Available-for-sale equity securities (other)

Available-for-sale money market funds (other)

Available-for-sale securities (other)

Average price paid per share (other)

Average share repurchase price (other)

BNT162b2 2021 revenue forecast (other)

BNT162b2 deferred revenues (other)

BNT162b2 revenue forecast (other)

Baxter goodwill (other)

Baxter identifiable intangible assets (other)

Baxter vaccines acquisition price (other)

Benefit plans: actuarial losses (other)

Benefit plans: prior service costs/credits (other)

Best-selling medicines (other)

Bextra market share (other)

Bextra new prescription share (other)

Billion-dollar products (other)

Biopharma products over $1B (other)

Biopharmaceutical products >$1B sales (other)

Biosimilars revenues (other)

Blockbuster products (other)

Branded prescription growth (other)

Brands (finite-lived) (other)

Brands (indefinite-lived) (other)

Brands and other (indefinite-lived) (other)

CAD to USD Exchange Rate (other)

CENCOEX exchange rate (other)

CNS product sales (other)

COVID-19 revenue impact (other)

COVID-19 vaccine doses delivered (other)

COVID-19 vaccine doses manufactured (other)

COVID-19 vaccine second doses administered (other)

COVID-19 vaccine trial enrollment (other)

Caduet markets approved (other)

Candidates advanced to Phase 1 (other)

Candidates advanced to Phase 2 (other)

Capital expenditures (other)

Capitalized interest (other)

Capsugel revenue (other)

Cardiovascular product sales (other)

Cardura net sales (other)

Cardura revenues (other)

Carrying value of Hisun Pfizer investment (other)

Cash and Cash Equivalents (other)

Cash and cash equivalents (other)

Cash and cash equivalents, beginning (other)

Cash and cash equivalents, end (other)

Cash collateral received (other)

Cash dividends paid (other)

Cash dividends paid per common share (other)

Cash dividends paid per share (other)

Category-leading products (other)

Celebrex new prescription share (other)

Celebrex worldwide sales (other)

Certain significant items (other)

Chantix/Champix prescriptions filled (other)

Chargebacks (other)

Clinical R&D Projects (other)

Clinical R&D pipeline projects (other)

Clinical R&D projects (other)

Clinical development programs (other)

Collateral posted (other)

Colleagues feeling engaged (other)

Comirnaty Revenue (other)

Comirnaty deferred revenue (other)

Comirnaty deferred revenues (other)

Comirnaty doses to low/middle-income countries (other)

Comirnaty forecasted revenue (other)

Comirnaty revenue forecast (other)

Commercial paper outstanding (other)

Commercial paper support (other)

Commercial structure reorganization costs (other)

Committed lines of credit (other)

Common Shares Outstanding (other)

Common Stock Shares Outstanding (other)

Common Stockholders (other)

Common Stockholders of Record (other)

Common shares outstanding (other)

Common shares purchased (other)

Common shares repurchased (other)

Common shares repurchased cumulative (other)

Common stock (other)

Common stock holders (other)

Common stock outstanding (other)

Common stock purchased (other)

Common stock purchases (other)

Common stock repurchased (other)

Common stock shares outstanding (other)

Common stockholders of record (other)

Compounds advanced (other)

Compounds advanced from discovery to preclinical (other)

Compounds advanced to preclinical (other)

Comprehensive income (other)

Concentration of credit risk (other)

Consecutive quarterly dividends (other)

Consumer Healthcare revenues (other)

Consumer products revenue (other)

Corporate debt (other)

Corporate earnings (other)

Corporate/Unallocated accrued compensation and related items (other)

Corporate/Unallocated current tax assets (other)

Corporate/Unallocated other current assets (other)

Corporate/Unallocated other current liabilities (other)

Corporate/Unallocated trade accounts payable (other)

Cost of sales (other)

Cost reduction costs incurred (other)

Cost reduction program costs incurred (other)

Cost reduction program spend (other)

Cost savings achieved (other)

Cost savings achieved from Hospira acquisition (other)

Cost savings target (other)

Cost synergies achieved (other)

Cost synergies from Pharmacia acquisition (other)

Cost synergies realized (other)

Cost-reduction costs incurred (other)

Costs incurred for new initiatives (other)

Costs incurred, 2017-2019 cost-reduction program (other)

Countries (other)

Countries Where We Sell (other)

Countries above revenue threshold (other)

Countries and territories served (other)

Countries and territories supplied (other)

Countries approved (other)

Countries exceeding $500M revenue (other)

Countries launched (other)

Countries of operation (other)

Countries of sale (other)

Countries over $500M (other)

Countries over $500M revenue (other)

Countries served (other)

Countries where products are sold (other)

Countries where products sold (other)

Countries with $10M+ sales (other)

Countries with >$10M sales (other)

Countries with >$500M revenue (other)

Countries with >$500M revenues (other)

Countries with Sales (other)

Countries with net sales (other)

Countries with net sales over $10 million (other)

Countries with net sales over $100 million (other)

Countries with operations (other)

Countries with over $500 million in revenue (other)

Countries with product sales (other)

Countries with products available (other)

Countries with revenue >$500M (other)

Countries with revenue above $500 million (other)

Countries with revenue over $500 million (other)

Countries with revenue over $500M (other)

Countries with revenues > $500M (other)

Countries with revenues >$500M (other)

Countries with sales (other)

Countries with significant revenue (other)

Cumulative cost of share repurchases (other)

Cumulative ongoing annual cost savings from 2014-2016 program (other)

Cumulative shares repurchased (other)

Cumulative workforce reduction (other)

Currency impact on sales (other)

Current deferred tax assets (other)

Current ratio (other)

Current tax assets (other)

Days of sales outstanding (other)

Days sales outstanding (other)

Debt securities maturities - Over 1 to 5 years (other)

Debt securities maturities - Over 10 years (other)

Debt securities maturities - Over 5 to 10 years (other)

Debt securities maturities - Within 1 year (other)

Debt to capitalization (other)

Debt to total capitalization (other)

Deferred Revenues (other)

Deferred revenues (other)

Deferred severance benefits (other)

Deferred tax liabilities (other)

Depot closures completed (other)

Derivative assets (other)

Derivative financial instruments (other)

Derivative financial instruments in a liability position (other)

Derivative financial instruments in a receivable position (other)

Derivative liabilities (other)

Detrol LA new prescription share (other)

Detrol/Detrol LA new prescription share (other)

Developed technology rights (other)

Diflucan net sales (other)

Diluted EPS (other)

Diluted Weighted-Average Shares Guidance (other)

Discovery projects (other)

Discovery research projects (other)

Dividend Per Share (other)

Dividend declared per share (other)

Dividend per share (other)

Dividends declared per share (other)

Dividends paid (other)

Dividends paid per share (other)

Dividends payable (other)

Dogs treated (other)

Drug candidates in development (other)

Due from bank counterparties (other)

EPA Penalty Demand (other)

Early-stage compounds (other)

Early-stage pipeline (other)

Early/mid-stage compounds in development (other)

Earnings per share (other)

Effective Tax Rate Guidance (other)

Effective tax rate (other)

Effective tax rate guidance (other)

Effexor XR Damages (other)

Effexor XR Net Liability (other)

Effexor revenues (other)

Eligible adults vaccinated (other)

Employee termination costs accrual (other)

Employees terminated (other)

Environment capex (other)

Environment-related capital expenditures (other)

Environment-related expenses (other)

Environmental capex (other)

Environmental capital expenditures (other)

Environmental compliance capex (other)

Environmental compliance expenses (other)

Environmental expenditures (other)

Environmental expenses (other)

Environmental operating expenses (other)

Environmental spending (other)

EpiPen revenues (other)

Equity attributable to noncontrolling interests (other)

Equity per common share (other)

Estimated remaining Year 2000 costs (other)

Ethnically diverse U.S. employees (other)

Ethnically diverse workforce (other)

Exit costs accrual (other)

Expected annual cost savings (other)

Expected contributions from general assets - International Pension Plans (other)

Expected contributions from general assets - Postretirement Plans (other)

Expected contributions from general assets - U.S. Qualified Pension Plans (other)

Expected contributions from general assets - U.S. Supplemental Pension Plans (other)

Expected cost savings (other)

Expected costs 2014-2016 (other)

Expected pension contributions (other)

Expected pension contributions 2014 (other)

Expected pension plan contributions (other)

Expected postretirement contributions (other)

Expected postretirement contributions 2014 (other)

Expected postretirement plan contributions (other)

Expected restructuring costs (other)

Expensed restructuring headcount (other)

Facilities closed (other)

Fair value of long-term debt (other)

Female workforce share (other)

Field force reduction (other)

Finite-lived intangible assets (other)

Forecasted 2023 revenues (other)

Forecasted Comirnaty revenues (other)

Forecasted Paxlovid revenues (other)

Foreign currency forward-exchange contracts (liability) (other)

Foreign currency forward-exchange contracts (receivable) (other)

Foreign currency loss from Venezuela devaluation (other)

Foreign currency swaps (liability) (other)

Foreign currency swaps (receivable) (other)

Foreign currency translation adjustments (other)

Foreign exchange impact on revenue (other)

Foreign exchange impact on revenues (other)

GEP accrued compensation and related items (other)

GEP cost of sales (other)

GEP current tax assets (other)

GEP earnings (other)

GEP other (income)/deductions—net (other)

GEP other current assets (other)

GEP other current liabilities (other)

GEP research and development expenses (other)

GEP revenues (other)

GEP selling, informational and administrative expenses (other)

GEP trade accounts payable (other)

GEP trade accounts receivable (other)

GIP accrued compensation and related items (other)

GIP cost of sales (other)

GIP current tax assets (other)

GIP earnings (other)

GIP other (income)/deductions—net (other)

GIP other current assets (other)

GIP other current liabilities (other)

GIP research and development expenses (other)

GIP revenues (other)

GIP selling, informational and administrative expenses (other)

GIP trade accounts payable (other)

GIP trade accounts receivable (other)

Generic prescription share (other)

Generic product share (other)

Geodon new prescription share (other)

Geodon prescription share (other)

Global field force reduction (other)

Goodwill (other)

Goodwill - EH (other)

Goodwill - IH (other)

Goodwill balance (other)

Government National Mortgage Association and other U.S. government guaranteed asset-backed securities (other)

Gross accounts receivable from challenging European markets (other)

Gross accounts receivable — stressed European sovereigns (other)

Gross carrying amount of finite-lived intangible assets (other)

Gross carrying amount of identifiable intangible assets (other)

Gross government receivables (other)

Gross identifiable intangible assets (other)

Guidance for 2017 adjusted cost of sales as a percentage of revenues (other)

Guidance for 2017 adjusted diluted EPS (other)

Guidance for 2017 adjusted other (income)/deductions (other)

Guidance for 2017 adjusted research and development expenses (other)

Guidance for 2017 adjusted selling, informational and administrative expenses (other)

Guidance for 2017 effective tax rate on adjusted income (other)

Guidance for 2017 revenues (other)

HRT actions settled (other)

Haleon ownership stake (other)

Health care R&D expense ratio (other)

Held-to-maturity debt securities (other)

High-revenue countries (other)

Hisun Pfizer Indirect Retained Interest Gain (other)

Hisun Pfizer Ownership (other)

Hisun Pfizer Pre-tax Gain (other)

Holders of record (other)

Hospira acquisition consideration (other)

Hospira benefit obligations (other)

Hospira cost savings achieved (other)

Hospira goodwill (other)

Hospira identifiable intangible assets (other)

Hospira in-process R&D (other)

Hospira long-term debt (other)

Hospira net assets acquired (other)

Hospira net income tax accounts (other)

Hospira other noncurrent assets (other)

Hospira other noncurrent liabilities (other)

Hospira property, plant and equipment (other)

Hospira working capital (other)

Hospital products net sales (other)

Hospital products sales (other)

Hospital products sales growth (other)

Human pharmaceutical revenue (other)

IPR&D (other)

Ibrance revenues (other)

Identifiable Intangible Assets (other)

Identifiable intangible assets (other)

Identifiable intangible assets - Brands (finite-lived) - EH (other)

Identifiable intangible assets - Brands (finite-lived) - IH (other)

Identifiable intangible assets - Brands (indefinite-lived) - EH (other)

Identifiable intangible assets - Brands (indefinite-lived) - IH (other)

Identifiable intangible assets - EH (other)

Identifiable intangible assets - IH (other)

Identifiable intangible assets - IPR&D - EH (other)

Identifiable intangible assets - IPR&D - IH (other)

Identifiable intangible assets - IPR&D - WRD (other)

Identifiable intangible assets - WRD (other)

Implementation completion (other)

Implementation progress (other)

In-process R&D (other)

Income taxes paid (other)

Income taxes payable (other)

Indefinite-lived intangible assets (other)

Infectious disease product sales (other)

Infusion Systems revenues (other)

Inlyta revenues (other)

Integration synergies (other)

Integration-related synergies (other)

Interest expense (other)

Interest paid (other)

Interest rate swaps (liability) (other)

Interest rate swaps (receivable) (other)

Internal manufacturing plants (other)

International revenue mix (other)

International revenue share (other)

International share of total revenues (other)

Inventory (other)

Inventory on hand (other)

Inventory turnover (other)

Inventory write-offs (other)

Invest-to-win pipeline compounds (other)

Key products sales share (other)

Largest wholesaler revenue concentration (other)

Late-stage drug candidates (other)

Late-stage new chemical entities (other)

Late-stage pipeline (other)

Late-stage pipeline candidates (other)

Late-stage pipeline programs (other)

Legacy Established Products revenues (other)

Legacy Hospira revenue contribution (other)

Legacy Wyeth revenue contribution (other)

Licensing agreements (other)

Licensing agreements and other (other)

Lines of credit available (other)

Lipitor countries launched (other)

Lipitor market share (other)

Lipitor prescription growth (other)

Lipitor prescription share (other)

Lipitor revenues (other)

Lipitor share advantage (other)

Long-term Debt (other)

Long-term debt (other)

Long-term debt - 0.00% euro notes (other)

Long-term debt - 0.25% euro notes (other)

Long-term debt - 1.00% euro notes (other)

Long-term debt - 3-month EURIBOR + 0.20% floating rate notes (other)

Long-term debt - 4.20% notes (other)

Long-term debt maturities (other)

Long-term debt maturities - 2018 (other)

Long-term debt maturities - 2019 (other)

Long-term debt maturities - 2020 (other)

Long-term debt maturities - 2021 (other)

Long-term debt maturities - After 2021 (other)

Long-term investments (other)

Lyrica market share (other)

Lyrica new prescription share (other)

Lyrica prescription share (other)

Lyrica revenues (other)

Major research sites (other)

Manufacturing plant network costs (other)

Manufacturing plant network reduction (other)

Manufacturing plant sites (other)

Manufacturing plants (other)

Manufacturing sites (other)

Manufacturing sites rationalized (other)

Manufacturing sites to exit (other)

Market share (other)

Market share prescriptions (other)

Markets over $500M (other)

Medicaid and related state program rebates (other)

Medicare rebates (other)

Medicines leading therapeutic areas (other)

Merger cost savings (other)

Merger restructuring reserve (other)

Merger-related cost savings (other)

Merger-related cost savings target (other)

Merger-related cost synergies (other)

Merger-related costs (other)

Merger-related synergies (other)

Metsera cost synergies (other)

Money market funds (other)

Months of inventory (other)

Months of inventory on hand (other)

Moody's commercial paper rating (other)

Moody's long-term debt rating (other)

Mortgage-backed securities (other)

Mylotarg payment obligation (other)

NMEs advanced to Phase 3 (other)

Net cash provided by operating activities (other)

Net cash used in financing activities (other)

Net cash used in investing activities (other)

Net financial assets (other)

Net finite-lived intangible assets (other)

Net income (other)

Net monetary assets in Venezuela (other)

Net periodic benefit cost (other)

Net periodic benefit income (other)

Net receivables from Greek government (other)

Net sales growth (other)

Net sales per employee (other)

Neurontin Antitrust Settlement (other)

Neurontin Settlement (other)

Neurontin revenues (other)

New Drug Applications intended (other)

New Drug Applications submitted (other)

New drug applications filed (other)

New drug candidates (other)

New drug candidates delivered to early development (other)

New prescription growth (other)

New prescription share (other)

Nexium OTC Future Milestones (other)

Nexium OTC Launch Milestone (other)

Nexium OTC Upfront Payment (other)

Non-monetary assets in Venezuela (other)

Noncurrent deferred tax assets (other)

Noncurrent deferred tax liabilities (other)

Nonvested stock options (other)

Norvasc net sales (other)

Norvasc revenues (other)

Number of Reportable Segments (other)

Operating cash flow (other)

Operational revenue growth (other)

Other (income)/deductions—net (other)

Other accruals for revenue deductions (other)

Other asset-backed debt (other)

Other business activities earnings (other)

Other comprehensive income (other)

Other cost of sales (other)

Other cost-reduction initiatives (other)

Other current assets (other)

Other current liabilities (other)

Other environmental expenses (other)

Other noncurrent assets (other)

Other noncurrent liabilities (other)

Other other (income)/deductions—net (other)

Other research and development expenses (other)

Other selling, informational and administrative expenses (other)

Other taxes payable (other)

Other unallocated (other)

Outsourced manufacturing (other)

Outsourced manufacturing share (other)

Outsourced product manufacturing (other)

Outstanding shares (other)

Ownership percentage of Hisun Pfizer (other)

Ownership percentage of ICU Medical (other)

Ownership percentage of Teuto (other)

Patients prescribed Chantix/Champix (other)

Patients treated (other)

Paxlovid Revenue (other)

Paxlovid forecasted revenue (other)

Paxlovid revenue forecast (other)

Paxlovid treatment courses (other)

Pending FDA filings (other)

Pending New Drug Applications (other)

Pending asbestos claims (other)

Pending claims (other)

Pension benefit obligations (other)

Pension plan contributions (other)

Performance share awards outstanding (other)

Performance-based contract rebates (other)

Peri-LOE Products revenues (other)

Peripheral stents sales (other)

Pfizer CentreOne revenues (other)

Pfizer asbestos cases (other)

Pfizer talc cases (other)

Pharmaceutical sales growth (other)

Pharmacia restructuring headcount (other)

Phase 3 development programs (other)

Phase 3 portfolio programs (other)

Phase 3 programs (other)

Phase III Programs (other)

Phase III portfolio programs (other)

Phase III programs (other)

Pipeline candidates advanced (other)

Pipeline products in regulatory review (other)

Pipeline programs (other)

Pipeline projects (other)

Pipeline projects in development (other)

Plan participants (other)

Planned R&D spend (other)

Planned manufacturing plants (other)

Planned workforce reduction (other)

Postretirement benefit obligations (other)

Postretirement plan contributions (other)

Pre-tax gain deferred in Accumulated other comprehensive loss (other)

Pre-tax gain reclassified (other)

Pre-tax loss deferred in AOCI (other)

Pre-tax loss expected to be reclassified (other)

Preferred stock (other)

Preferred stock dividends (other)

Premarin family revenues (other)

Prescription growth (other)

Prescription market share (other)

Prescription share (other)

Prescriptions written (other)

Prevnar 13 adult vaccination coverage (other)

Prevnar 13 approvals (other)

Prevnar 13 countries (other)

Prevnar 13 countries approved (other)

Prevnar 13 countries launched (other)

Prevnar 13 country approvals (other)

Prevnar 13 country launches (other)

Prevnar/Prevenar 13 revenues (other)

Price impact on revenues (other)

Primary therapeutic areas (other)

Prior service costs/credits (other)

Priority late-stage share (other)

Priority research share (other)

Private equity securities (other)

Procardia XL net sales (other)

Product net sales (other)

Product revenue (other)

Product sales (other)

Product sales growth (other)

Production plants (other)

Products outsourced (other)

Products outsourced manufacturing (other)

Products over $1 billion (other)

Products over $1 billion in sales (other)

Products over $1B revenue (other)

Products over $2 billion in sales (other)

Products ranked #1 in therapeutic category (other)

Products ranked first (other)

Products under regulatory review (other)

Products with $1B+ revenues (other)

Products with $1B+ sales (other)

Products with >$1B Revenue (other)

Products with >$1B revenue (other)

Products with >$1B sales (other)

Products with over $1 billion in sales (other)

Products with over $1 billion revenue (other)

Products with over $1B revenue (other)

Products with revenue over $1 billion (other)

Products with revenue over $1B (other)

Products with ≥$2B revenue (other)

Projects in Clinical R&D (other)

Projects in development (other)

Property, plant and equipment (other)

Provision for taxes on income (other)

Purchase accounting adjustments (other)

Quigley asbestos cases (other)

R&D Expense (other)

R&D Expenses (other)

R&D Investment (other)

R&D Programs (other)

R&D Programs Phase 1 through Registration (other)

R&D Projects (other)

R&D Projects in Development (other)

R&D Spending (other)

R&D budget (other)

R&D discovery projects (other)

R&D expenditures (other)

R&D expense (other)

R&D expenses (other)

R&D investment (other)

R&D pipeline (other)

R&D pipeline compounds (other)

R&D pipeline projects (other)

R&D portfolio focus (other)

R&D programs in Phase 1 through registration (other)

R&D projects (other)

R&D projects in Phase 1 through registration (other)

R&D projects in development (other)

R&D projects in pipeline (other)

R&D site transfers completed (other)

R&D sites (other)

R&D spending plan (other)

Ratio of current assets to current liabilities (other)

Ratio of earnings to fixed charges (other)

Rebate accruals (other)

Rebate and chargeback accruals (other)

Rebate impact on revenues (other)

Rebates and chargebacks (other)

Rebates and chargebacks accrual (other)

Receivables in excess of one year (other)

Receivables in excess of one year - Greece (other)

Receivables in excess of one year - Italy (other)

Receivables in excess of one year - Portugal (other)

Receivables in excess of one year - Spain (other)

Receivables in excess of one year from invoice date (other)

Record holders (other)

Record holders of common stock (other)

Relpax prescription share (other)

Relpax revenues (other)

Remaining buyback authorization (other)

Remaining repurchase authorization (other)

Remaining share repurchase authorization (other)

Remaining share-purchase authorization (other)

Remaining share-repurchase authorization (other)

Rents (other)

Reported diluted EPS (other)

Research and development expense (other)

Research and development expenses (other)

Research projects (other)

Research sites (other)

Restricted stock and private equity securities (other)

Restricted stock units outstanding (other)

Restructuring accrual (other)

Restructuring accrual balance (other)

Restructuring accruals (other)

Restructuring annualized benefit (other)

Restructuring annualized savings (other)

Restructuring charges (other)

Restructuring charges and certain acquisition-related costs (other)

Restructuring costs incurred (other)

Restructuring program completion (other)

Restructuring program costs incurred (other)

Restructuring reserve (other)

Restructuring reserve utilization (other)

Restructuring reserves remaining (other)

Restructuring savings (other)

Restructuring target benefit (other)

Restructuring terminations (other)

Retained earnings (other)

Revenue (other)

Revenue by geography (other)

Revenue by product (other)

Revenue by segment (other)

Revenue change currency (other)

Revenue change price (other)

Revenue change volume (other)

Revenue concentration of top products (other)

Revenue deductions (other)

Revenue deductions accrual (other)

Revenue from U.K. (other)

Revenue from international operations (other)

Revenue from operations outside the U.S. (other)

Revenue from top products (other)

Revenue growth (other)

Revenue growth - price (other)

Revenue growth - volume (other)

Revenue growth currency (other)

Revenue growth drivers (other)

Revenue growth ex-FX (other)

Revenue growth excluding currency (other)

Revenue growth excluding currency and accounting harmonization (other)

Revenue growth from price (other)

Revenue growth from volume (other)

Revenue growth price (other)

Revenue growth volume (other)

Revenue guidance (other)

Revenue outside U.S. (other)

Revenue outside the United States (other)

Revenue per employee (other)

Revenue price change (other)

Revenues from Greece (other)

Reverse repurchase agreements (other)

Rezulin claims settled or withdrawn (other)

Rimadyl sales (other)

Rimadyl-treated dogs (other)

Rocky Mount injectables share (other)

S&P commercial paper rating (other)

S&P long-term debt rating (other)

SGR Repeal Cost Estimate (other)

SICAD I exchange rate (other)

SICAD II exchange rate (other)

Sales allowances (other)

Sales growth (other)

Sales growth currency (other)

Sales growth price (other)

Sales growth rate (other)

Sales growth volume (other)

Sales price growth (other)

Sales representatives (other)

Sales returns and cash discounts (other)

Sales volume growth (other)

Segment profit (other)

Selected net financial assets/(liabilities) (other)

Selected net financial liabilities (other)

Selling, informational and administrative expenses (other)

Share Repurchase Authorization Remaining (other)

Share of revenue from international operations (other)

Share repurchase authorization (other)

Share repurchase authorization remaining (other)

Share repurchases (other)

Shareholders of record (other)

Shareholders' Equity (other)

Shareholders' equity per common share (other)

Shareholders' equity per share (other)

Shares Outstanding (other)

Shares available for award (other)

Shares of common stock outstanding (other)

Shares outstanding (other)

Shares purchased (other)

Shares repurchased (other)

Short-term Investments (other)

Short-term borrowings (other)

Short-term borrowings - Commercial paper (other)

Short-term investments (other)

Sites identified for rationalization (other)

Sites to exit (other)

Sterile Injectable Pharmaceuticals revenues (other)

Stock options outstanding (other)

Strategic National Stockpile courses (other)

Strategic stockpile courses (other)

Supplier finance program obligation (other)

Supranational debt (other)

Sutent patients treated (other)

Sutent revenues (other)

Tablets dispensed (other)

Talc cases pending (other)

Target annual cost reduction (other)

Targeted annual cost reduction (other)

Targeted savings from 2017-2019 cost-reduction initiatives (other)

Therapeutic area leaders (other)

Therapeutic area leading medicines (other)

Third-party trade sales (other)

Tikosyn revenues (other)

Time deposits and other (other)

Top 10 product share (other)

Top 3 wholesaler revenue concentration (other)

Top 5 product share (other)

Top products sales share (other)

Total Assets (other)

Total Equity (other)

Total Liabilities (other)

Total Pfizer Inc. shareholders' equity (other)

Total Pfizer Inc. shareholders' equity per common share (other)

Total Pfizer Inc. shareholders’ equity per common share (other)

Total accumulated other comprehensive loss (other)

Total assets (other)

Total common stock purchases (other)

Total costs for 2014-2016 cost-reduction program (other)

Total current assets (other)

Total current liabilities (other)

Total debt (other)

Total debt securities (other)

Total deductions from revenues (other)

Total earnings as defined (other)

Total equity (other)

Total fixed charges (other)

Total goodwill (other)

Total identifiable intangible assets (other)

Total identifiable intangible assets, net (other)

Total liabilities (other)

Total long-term debt (other)

Total prescription share (other)

Total prescriptions (other)

Total revenue deductions (other)

Total selected financial assets (other)

Total selected financial liabilities (other)

Trade Secrets Verdict (other)

Trade accounts payable (other)

Trade accounts payable - Corporate/Unallocated (other)

Trade accounts payable - EH (other)

Trade accounts payable - IH (other)

Trade accounts receivable (other)

Trade accounts receivable - EH (other)

Trade accounts receivable - IH (other)

Trading funds and securities (other)

Trading securities (other)

Treasury stock (other)

Treatment courses returned (other)

Trovan sales (other)

U.S. ethnic diversity (other)

U.S. government debt (other)

U.S. government guaranteed ABS (other)

U.S. prescription share (other)

US prescription growth (other)

Unrealized holding gains on available-for-sale securities (other)

Unrealized holding losses on derivative financial instruments (other)

Unrealized pre-tax losses to be reclassified (other)

Unrealized pre-tax net gains on derivative financial instruments estimated to be reclassified into income within the next 12 months (other)

Unused lines of credit (other)

Unutilized restructuring reserve (other)

Unutilized restructuring reserves (other)

Upjohn global brands (other)

Upjohn globally recognized brands (other)

VOC accrued compensation and related items (other)

VOC cost of sales (other)

VOC current tax assets (other)

VOC earnings (other)

VOC other (income)/deductions—net (other)

VOC other current assets (other)

VOC other current liabilities (other)

VOC research and development expenses (other)

VOC revenues (other)

VOC selling, informational and administrative expenses (other)

VOC trade accounts payable (other)

VOC trade accounts receivable (other)

Vaccine authorized countries (other)

Vaccine doses under supply agreements (other)

Venezuela net monetary assets (other)

Venezuela non-monetary assets (other)

Viagra countries launched (other)

Viagra market share (other)

Viagra revenues (other)

Viagra sales (other)

ViiV Healthcare Equity Interest Reduction (other)

Voting common shares outstanding (other)

Weekly prescription share (other)

Weighted-average basic shares (other)

Weighted-average diluted shares (other)

Weighted-average lease term (other)

Weighted-average shares (other)

Weighted-average shares basic (other)

Weighted-average shares diluted (other)

Western European agency debt (other)

Western European agency debt (HTM) (other)

Western European government debt (other)

Western European government debt (HTM) (other)

Western European, Scandinavian and other government agency debt (other)

Western European, Scandinavian and other government debt (other)

Wholesaler inventory supply (other)

Wholesaler revenue concentration (other)

Women in workforce (other)

Workforce diversity (other)

Workforce reduction (other)

Workforce reduction target (other)

Workforce reductions completed (other)

Working capital (other)

World's best-selling medicines (other)

Xalatan/Xalacom revenues (other)

Xalkori revenues (other)

Xanax/Xanax XR revenues (other)

Xeljanz US Prescription Volume Growth (other)

Y2K implementation progress (other)

Year 2000 compliance cost (other)

Year 2000 compliance cost incurred (other)

Year 2000 compliance costs incurred (other)

Year 2000 costs incurred (other)

Year 2000 implementation completion (other)

Year 2000 program cost (other)

Year 2000 remediation cost (other)

Year 2000 remediation costs estimated (other)

Year 2000 remediation costs incurred (other)

Zithromax net sales (other)

Zithromax script share (other)

Zithromax/Zmax revenues (other)

Zoetis Cash Proceeds (other)

Zoetis Gain on Divestiture (other)

Zoetis IPO Consideration (other)

Zoetis IPO Shares Sold (other)

Zoetis Ownership Interest (other)

Zoetis Senior Notes Exchanged for Commercial Paper (other)

Zoetis Senior Notes Issued (other)

Zoloft net sales (other)

Zoloft revenues (other)

Zyrtec US sales (other)

Zyrtec sales (other)

Patients treated (patients)

Prescriptions filled (prescriptions_filled)

Comirnaty doses manufactured (production_volume)

Major manufacturing facilities (properties)

Remaining performance obligations (rpo)

Common stock shares outstanding (shares)

Weighted-average shares diluted (shares_outstanding)

Short-term borrowings (short_term_debt)

La Jolla R&D space (square_footage)

Chantix countries approved (stores)

Total assets (total_assets)

Total equity (total_equity)

Total liabilities (total_liabilities)

Comirnaty doses delivered (units_shipped)

Outsourced manufacturing (utilization_rate)

Workforce Totals

Demographics

Workforce Breakdowns

HCM Metrics — Point-in-Time

HCM Metrics — Flow (Annual / YTD)

Workforce Actions